



SciFinderⁿ hakkında özet bilgi:

SciFinderⁿ programını geliştiren Chemical Abstracts Service (CAS), American Chemical Society (ACS)'nin bir birimidir, dünyadaki en geniş kimya ve kimya ile ilgili literatür veritabanına sahiptir.

SciFinderⁿ özellikle Kimya ve İlaç firmaları, Kimya ve Kimya ile ilgili bölümler; Biyoloji, Fizik, Eczacılık, Tıp, Kimya Mühendisliği, Çevre Mühendisliği, Gıda Mühendisliği, Polimer Mühendisliği, Malzeme ve Metalürji Mühendisliği, Farmakoloji, Nanoteknoloji, Tekstil Mühendisliği, Enerji Sistemleri Mühendisliği, Biyomedikal Mühendisliği, Ziraat Mühendisliği, Jeoloji Mühendisliği vb. bölümlerin kullanabilecekleri önemli bir programdır.

SciFinderⁿ içeriğinde bulunan veritabanları;

CAplus (Referans Kaynaklar) | **CAS REGISTRY** (Kimyasallar) | **CASREACT** (Kimyasal Reaksiyonlar)

MARPAT (Markush Kimyasalları) | **CHEMLIST** (Kimyasal Regülasyon) | **CHEMCATS** (Kimyasal Sağlayıcı Katalogları)

CAplus (Referans Kaynaklar)

52 milyon üzeri kimya ve kimya ile ilgili alanlardaki araştırma kaydı içerir, bu kayıtlar **makale, patent konferans bildirimleri, sempozyum, kitap, teknik rapor ve doktora tezlerini** içermekte, 1907'den günümüze kadar olan literatürü kapsamaktadır.

10500'ün üzerinde fen bilimleri ile ilgili **akademik dergiyi** taramaktadır. Toplamda günümüze kadar **50000'**den fazla dergi indekslenmiştir.

63 patent ofisinden gelen **patentler** taranabilmektedir. **PatentPak** modülü sayesinde patentler çok daha kolay incelenebilmektedir.

İçerik indeksleri, bilim adamları tarafından oluşturulmuştur. İngilizce dışında farklı dillerde yazılmış (50'den fazla dil) makale özetleri, İngilizce'ye çevrilerek sunulmaktadır.

Citation Map özelliği eklenmiştir.

CAS REGISTRY (Kimyasallar) & CASREACT (Kimyasal Reaksiyonlar)

162 milyon üzeri **organik ve anorganik madde**

127 milyon üzeri **kimyasal reaksiyon**

68 milyon üzeri **protein ve nükleik asit dizisi (sequences)**


7,6 milyar üzeri **kimyasal özellik bilgisi**

108 milyondan fazla H- ve C- NMR spectra arşivi bünyesinde bulundurup, bunları tarama olanağı sağlamaktadır.


SciFinderⁿ ile kimyasal ve reaksiyonların çizimi yapılarak ilgili literatür bilgilerine ulaşılabilir.

Retrosentez özelliği ile deneysel ve tahmini retrosentez planlaması yapılabilir.

SciFinderⁿ arama arayüzü;



Referansların gösterimi;



Referansa tıkladığında gelen detaylar;

Go to References screen.

Retrieve data for reference.

Access an interactive version of the patent PDF that highlights the specific location of indexed substances.

View previous or next reference.

Access map of references this document cites, and references that cite this document.

Download, email, or save reference.

Access other full-text options.

PDF displays original patent PDF. PDF+ displays patent PDF with table of important chemistry. Viewer displays interactive version of PDF in PatentPak Viewer.

Click to view patent family member on Reference Detail screen.

Expand to view concepts that characterize the general subject matter of the document.

Expand to view substances associated with document.

Expand to view citations from this document.

Reference Detail (5 of 4,015)

Substances (12) Reactions (0) Cited By (1) PATENTPAK Viewer Citation Map

Patent

Patent Information

Patent Number: WO2015058034
 Publication Date: 2015-04-23
 Application Number: WO2014-US61038
 Application Date: 2014-10-17
 Kind Code: A1

Assignee
 The Regents of the University of Colorado, A Body Corporate, United States

Source
 World Intellectual Property Organization

Database Information
 AN: 2015:690500
 CAN: 162:544597
 CAplus

Language
 English

Use of tyrosine kinase inhibitor in cancer treatment
 By: Reyland, Mary E.; Wie, Sten; Degregori, James

Abstract: The invention provides methods for reducing apoptosis of non-cancerous cells during a cancer treatment and beneficial effects associated with reducing such apoptosis. In particular, methods of the invention comprise administering a tyrosine kinase inhibitor to a cancer patient who is undergoing cancer treatment in order to reduce apoptosis of non-cancerous cells. In another aspect of the invention the tyrosine kinase inhibitor is selected from the group consisting of dasatinib, imatinib, ponatinib, saracatinib, and a combination thereof.

Figure 1: Experimental timeline and results. Panel A shows a timeline from 0 hr to 90 days with treatments (+TKI, -TKI) and saliva collection. Panels B, C, and D are bar graphs showing Saliva Flow / Weight for Control, Dasatinib, IR, and IR+Dasatinib groups at different time points (0, 63, 90 days).

Patent Family

Patent	Language	Kind Code	PatentPak Options	Publication Date	Application Number	Application Date
WO2015058034	English	A1	PDF PDF+ Viewer	2015-04-23	WO2014-US61038	2014-10-17
US2013-61893132P		P			US2013-61893132P	2013-10-18
US2016-1515029617	English	A1	PDF	2016-08-11	US2016-1515029617	2016-04-14

Concepts

- Substances
- Citations (2)

Substances (12)

Substance Role: Pharmacological Activity (7)

- 943319-70-8: C21H27N5O Benzamide, 3-(2-imidazolyl-2-ethylpiperidin-3-yl)ethy...
- 380843-75-4: C21H27N5O2 3-Quinolonecarboxonitrile, 4-[2,4-dichloro-5-methox...
- 379231-04-6: C21H27N5O2 4-Quinolonecarboxamide, N-(5-chloro-1,3-benzodioxol-4-yl)...

Substance Role: Therapeutic Use (7)

Kimyasallarla ilgili arayüz;

The image shows the SciFinder web interface with several callout boxes highlighting key features:

- Retrieve data related to answers.** Points to the search bar and the 'Substances (6)' header.
- Download answers to an external file.** Points to the download icon (floppy disk) in the top right.
- Change how answers are displayed.** Points to the 'View Full' dropdown menu.
- Select type of structure match.** Points to the 'Substructure (6)' selection in the 'Structure Match' sidebar.
- Select filters to focus answers.** Points to the 'Filter by' section in the sidebar, including 'Commercial Availability', 'Reaction Role', and 'Reference Role'.
- Go to Substance Detail screen.** Points to the 'View Detail' link for the first substance entry.
- Retrieve data for substance.** Points to the 'Key Physical Properties' table for the first substance.
- View Key Physical Properties on Substance Detail screen.** Points to the 'Key Physical Properties' table for the second substance.
- Share answers by emailing link.** Points to the email icon in the top right.
- Save answers.** Points to the 'Save' icon in the top right.

The interface displays a list of substances with their chemical structures and key physical properties. The first substance is 1219937-98-0, and the second is 1416321-38-4. Both are identified as Cyclopropanecarbonyl chloride, 1-[[4-fluorophenyl]amino]carbonyl-.

Key Physical Properties	Value	Condition
Molecular Weight	276.09	-
Boiling Point (Predicted)	404.4±30.0 °C	Press: 760 Torr
Density (Predicted)	1.504±0.06 g/cm ³	Temp: 20 °C; Press: 760 Torr
pKa (Predicted)	13.86±0.70	Most Acidic Temp: 25 °C

Key Physical Properties	Value	Condition
Molecular Weight	276.09	-
Boiling Point (Predicted)	428.6±45.0 °C	Press: 760 Torr
Density (Predicted)	1.600±0.06 g/cm ³	Temp: 20 °C; Press: 760 Torr
pKa (Predicted)	13.18±0.70	Most Acidic Temp: 25 °C

Reaksiyonlarla ilgili arayüz;

Go to Reactions screen.

View previous or next reaction.

Download answers to an external file.

Share answers by emailing link.

Save data.

Click any substance image or name to display substance menu. Use menu options to view substance details (CAS Registry Number), zoom image (magnifier), retrieve associated information (Reactions, Suppliers, References), or copy substance to editor (Edit Substance).

Retrieve suppliers for substance.

View reaction reference on Reference Detail screen.

View full-text PDF for the patent reference or Patent Family members.

Access other full-text options.

Return to All Reaction Schemes

Reaction Detail (Scheme 1, Reaction 2 of 20)

← Prev Next →

Steps: 1

Save

Suppliers (2) Suppliers (25) Suppliers (55)

Step 1

Stage	Reagents	Catalysts	Solvents	Conditions
1	Potassium carbonate	-	Tetrahydrofuran Water	10 min, > 30 °C
2	Water	-	-	10 h, 15 - 30 °C

CAS Reaction Number 31-365-CAS-4160897

Alternative Steps (19)

Reference
Method of treating cancer and bone cancer pain
View Reference Detail
By: Schwab, Gisela; et al
World Intellectual Property Organization, WO2012151326 A1
2012-11-08

PATENTPAK Full Text

Patent Information
Patent Number
WO2012151326
Publication
2012-11-08
Application Number
WO2012-US36191
Application Date
2012-05-02
Kind Code
A1
Assignee
Exelixis, Inc., United States

Notes
alternative reaction conditions shown

Experimental Protocols

Experimental Procedure

Preparation of N-(4-((6,7-bis(methoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide The solution from the previous step containing 1-(4-fluoro-phenyl)carbonyl-cyclopropanecarbonyl chloride was added to a mixture of 4-(6,7-dimethoxy-quinoline-4-yl)oxy)phenylamine (3.0 kg), and potassium carbonate (4.0 kg) in THF (27.0 kg), and water (13.0 kg) at a rate such that the hatch temperature did not exceed 3.0 °C. When the reaction was complete (approximately 10 minutes), water (74.0 kg) was added. The mixture was stirred at 15 to 300 °C for approximately 10 hours, which resulted in the precipitation of the product. The product was recovered by filtration, washed with a pre made solution of THF (11.0 kg) and water (24.0 kg), and dried at approximately 659 °C under vacuum for approximately 12 hours to afford the title compound. Yield (free base, 5.0 kg). ¹H NMR (400 MHz, d₆-DMSO): δ 10.2 (s, 1 H), 10.05 (s, 1H), 8.4 (s, 1H), 7.8 (m, 2H), 7.65 (m, 2H), 7.5 (s, 1H), 7.35 (s, 1H), 7.25 (m, 2H), 7.15 (m, 2H), 6.4 (s, 1H), 4.0 (d, 6H), 1.5 (s, 4H) LC/MS: M-H = 502.

Retrosentez ile ilgili arayüz;

The screenshot displays the ChemPlanner Retrosynthesis interface. At the top, it says "Retrosynthesis" with "Edit Plan Options" and "Edit Plan" buttons. The main area shows a reaction plan starting from a starting material (A) with an average yield of 73%. The plan branches into several steps (B, C, D, E, F, G, I) with their respective maximum yields and the number of suppliers available for each substance. Key interactive features are highlighted with callouts:

- View Plan Steps:** Located in the top left, it allows users to view the overall reaction plan.
- Collapse Pane:** A button to collapse the left sidebar.
- Toggle Predicted Steps:** A switch to toggle between experimental and predicted steps.
- Highlight Step Substances:** A button to highlight specific substances in the plan.
- View/Select Alternative Steps:** A button to view or select alternative reaction steps.
- Zoom Plan View:** A button to zoom in or out of the reaction plan, with a "Reset" button below it.
- View Substance Information:** A button to view detailed information for a specific substance.
- View Substance Suppliers:** A button to view the list of suppliers for a specific substance.
- Download Plan:** A button to download the reaction plan.
- Share Plan:** A button to share the reaction plan.
- Save Plan:** A button to save the reaction plan.

Plan Information:

- Estimated Yield: 27%
- Overall Price: \$262,564.46 (USD per 100 grams)
- Commercially Available: B, C, D, E, F, G, H, I

Geçmiş aramalar ile ilgili arayüz;

The screenshot displays the SciFinder Search History interface. On the left, there is a 'Filter by' section with 'Search Type' and 'Date' filters. The 'Search Type' section includes options for All (23), Substances (542), Reactions (258), Retrosynthesis (9), References (850), and Suppliers (27). The 'Date' section includes a calendar for April 2018. The main area is titled 'Search History (859)' and shows a list of search results. Two callout boxes are present: one labeled 'Search history' pointing to the top right navigation area, and another labeled 'Saved Searches' pointing to the 'Saved Searches' button in the top right navigation area. The search results are grouped by date: April 25, 2018 (5:19 PM, References: theory of relativity (1.5M), Rerun Search), April 24, 2018 (4:36 PM, References: Advanced Search (745), Author: Laird, E., Rerun Search), and April 19, 2018 (1:25 PM, Retrosynthesis: Synthetic Depth: 3, Rules Supporting Predictions: Uncommon, Break & Protect Bonds: No, Open Plan Complete) and (1:20 PM, Retrosynthesis: Synthetic Depth: 4, Rules Supporting Predictions: Uncommon, Break & Protect Bonds: No, Open Plan Complete).

Citation Map

🔍 Citation Map

Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine

By: Pankhanla, Mahendra Govind; Yurdakul, Saruhan
World Intellectual Property Organization, WO9834612
A1 1998-08-13 | Language: English, Database: Caplus
[View Reference Detail](#)

PATENTPAK ▾
Full Text ▾

Abstract: Migraine is treated by administering to the patient a pharmaceutical composition containing a therapeutically effective amount of ibuprofen or a salt thereof and a therapeutically effective amount of domperidone or a salt thereof. A pharmaceutical tablet contained ibuprofen 60, domperidone 1.5, tricalcium phosphate 18.50, microcrystalline cellulose 5.9, PVP 3.9, croscarmellose sodium 9.6, and stearic acid 0.6%.

Filter by

^ **Document Type**

- Journal (1)
- Patent (8)
- Clinical Trial (1)

^ **Author**

- Highton, Frederick Raymond (2)
- Rhoades, Tracey Jane (2)
- Sherry, Robert Arthur (2)
- Brunelle, Alan (1)
- Dickinson, Jeffrey (1)

[View All](#)

^ **Concept**

- Pharmaceutical tablets (7)
- Nonsteroidal anti-inflammatory agents (3)
- Pharmaceutical capsules (3)
- Pharmaceutical granules (3)
- Analgesics (2)

[View All](#)

References This Document Cites

Domperidone and NSAIDS for the treatment of migraine

No Source data available (1997)

Cited By 3 📍 Map

Tablet formulations for migraine treatment

No Source data available (1991)

Cited By 3 📍 Map

The role of a peripheral dopamine-antagonist (Motilium) in improving the tolerance to steroidal and non-steroidal anti-inflammatory agents.

Therapia Hungarica (English edition) (1990)

Cited By 1 📍 Map

References Citing This Document

Medicinal compositions comprising a core and a film based on modified cellulose derivatives

No Source data available (2004)

Citing 4 📍 Map

Compressed tablet formulation comprising non-steroidal anti-inflammatory drugs and methods

No Source data available (2012)

Citing 1 📍 Map

Ibuprofen tablet formation with additives such as silicon dioxide and cellulose

No Source data available (2008)

Citing 0 📍 Map

Compressed tablets comprising granular component containing NSAIDS

No Source data available (2001)

Citing 0 📍 Map

Pharmaceutical combination of ibuprofen lysine and domperidone for treating migraine

No Source data available (2000)

Citing 0 📍 Map

Pharmaceutical compositions comprising ibuprofen and domperidone

No Source data available (2000)

Citing 0 📍 Map

Only citations that have reference detail records will appear.